Commentary: Objective aids for the assessment of ADHD – further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016). (June 2016)

• Record Type: Journal Article
• Authors: Stein, Mark A.; Snyder, Steven M.; Rugino, Thomas A.; Hornig, Mady
• Is Part Of: Journal of child psychology and psychiatry and allied disciplines. Volume 57:Number 6(2016)
• Page Start: 770
• Page End: 771
• Publication Date: 2016-06
• Subjects: Child psychology -- Periodicals; Child psychiatry -- Periodicals; 155.4
• DOI: 10.1111/jcpp.12534
• Languages: English
• ISSNs: 0021-9630

Abstract

Abstract : Neuropsychiatric EEG‐Based ADHD Assessment Aid (NEBA) is an EEG‐based device designed to aid in the diagnostic process for ADHD by identifying individuals less likely to have ADHD by virtue of a lower theta/beta ratio. In using NEBA as an example, the Arns et al. commentary misstates the purpose of NEBA, which is to widen the differential rather than to make the diagnosis. Arns et al. caution about missing an ADHD diagnosis, but fail to mention the impact of overdiagnosis. If we are to advance our knowledge of the etiology and pathophysiology of ADHD, as well as develop tailored treatments and ultimately improve outcomes for ADHD, then biomarkers and objective assessment aids such as NEBA are needed to improve and refine diagnostic accuracy beyond symptom description and clinical history. Abstract : Read the full article at doi:10.1111/jcpp.12524